FDA Inspection 1120136 — Jubilant Cadista Pharmaceuticals

Jubilant Cadista Pharmaceuticals — FEI 3017221809

The FDA completed an inspection of Jubilant Cadista Pharmaceuticals on Feb 28, 2020 in Yardley, PA. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). 3 citations were issued during this inspection. Product area: Drugs.

Inspection details

Classification
Voluntary Action Indicated (VAI)
End Date
Feb 28, 2020
Fiscal Year
2020
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Yardley, PA (United States)

Citations

IDCFRDescription
145021 CFR 211.113(a)Procedures for non-sterile drug products
2153621 CFR 514.80(b)(1)Applicant did not submit/submitted late 3-Day Field Alert Report or wrong format
438921 CFR 211.198(a)Procedures to be written and followed

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.